title: [Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer].
abstract: Forty-nine patients with unresectable pancreatic cancer (stage IV disease) received gemcitabine in a multi-center trial in the Fukuoka pancreatic cancer chemotherapy group, Japan. No complete remissions, 5 partial remissions (10%) and 25 no changes (51%) were obtained. Gemcitabine could maintain QOL. Main toxicities were hematologic, especially neutropenia. Neutropenia tended to appear in early administration. Non-hematologic toxicities were anorexia, nausea/vomiting, and skin rash. The mean overall survival period was 7.5 months. Carcinomatous ascites and/or pleural effusion resulted in a poor prognosis (average survival 3.1 months). Gemcitabine could be given without severe toxicities in outpatient clinics. These results suggested that gemcitabine is currently a first-line therapeutic agent for advanced pancreatic cancer.
authors.affiliation: Dept. of Gastroenterology, National Kyushu Cancer Center.
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Sumii
authors.forename: Akihiro
authors.initials: A
authors.lastname: Funakoshi
authors.forename: Tetsuhide
authors.initials: T
authors.lastname: Ito
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Mizumoto
authors.forename: Masao
authors.initials: M
authors.lastname: Tanaka
authors.forename: Yoshikatsu
authors.initials: Y
authors.lastname: Migita
authors.forename: Terufumi
authors.initials: T
authors.lastname: Sakai
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Shinozaki
authors.forename: Hiroya
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Niyahara
authors.forename: Toru
authors.initials: T
authors.lastname: Muranaka
authors.forename: Naofumi
authors.initials: N
authors.lastname: Eriguchi
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Ueki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D006801:Humans; D017567:Karnofsky Performance Status; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D014840:Vomiting, Anticipatory / Q000209:etiology; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine